Overview
In survivors of oropharyngeal cancer, late treatment effects can be just as important as the original cancer itself. One underrecognized complication is hypoglossal neuropathy, which refers to injury or dysfunction of the twelfth cranial nerve (CN XII). This nerve controls movement of the tongue. When it is affected, people may develop subtle but progressive problems with speech, swallowing, chewing, and managing saliva or mucus. Because these changes often appear gradually after treatment, CN XII neuropathy can be missed until it becomes clinically obvious.
This cohort study examined whether patient-reported symptoms captured by the MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) could help identify patients at higher risk for developing CN XII neuropathy earlier than routine clinical follow-up alone. The findings suggest that a small set of symptom questions, especially speech and voice changes, may serve as a practical screening tool for survivorship care.
Why hypoglossal neuropathy matters after oropharyngeal cancer
The oropharynx includes structures such as the tonsils, base of tongue, soft palate, and surrounding throat tissues. Cancers in this region are often treated with radiation therapy, chemotherapy, surgery, or a combination of these approaches. Although treatment can be curative, nearby nerves may be exposed to radiation or surgical injury. The hypoglossal nerve is particularly important because tongue motion is essential for speaking clearly, forming a food bolus, and safely moving food and liquids through the throat.
When CN XII is damaged, patients may notice a slurred or effortful voice, difficulty chewing certain foods, choking episodes, tongue weakness, or a sense that swallowing is less coordinated. These symptoms can overlap with more common side effects of treatment, such as dry mouth, thick saliva, fatigue, and swallowing discomfort. That overlap makes early diagnosis challenging.
Study purpose
The investigators aimed to determine whether selected symptom items from the MDASI-HN questionnaire could predict the future development of CN XII neuropathy. They also sought to create a composite score, called MDASI-HN-NERVE, that would combine several relevant symptoms into a single risk measure. The ultimate goal was to identify patients at risk earlier so that clinicians could monitor them more closely and potentially intervene sooner.
How the study was done
This was a retrospective analysis of prospectively collected data from 1,297 patients with oropharyngeal cancer treated with curative intent at MD Anderson Cancer Center between March 2015 and December 2023. Patients completed symptom surveys at baseline and at regular follow-up visits for up to five years.
The study team reviewed health records to classify whether CN XII neuropathy had occurred, based on documented clinical signs. They then examined symptom patterns for six MDASI-HN items that were thought to be most relevant to nerve dysfunction: chewing/swallowing, choking, speech/voice, mucus, fatigue, and dry mouth.
To understand how these symptoms changed over time, the researchers used visual trajectory plots and statistical models that could account for repeated measurements in the same patient. They then built the MDASI-HN-NERVE score from the selected items and tested whether higher scores were associated with a higher risk of later CN XII neuropathy. They also used survival analysis methods to identify cut-off values that best separated high-risk from low-risk patients.
Key findings
Among the 1,297 participants, most were men, reflecting the typical demographics of oropharyngeal cancer cohorts. The mean age was 65.9 years. During follow-up, the study found that higher MDASI-HN-NERVE scores were linked to an increased risk of CN XII neuropathy. The hazard ratio was 1.35, meaning that as the score increased, the risk of neuropathy rose meaningfully as well.
The researchers identified useful thresholds for risk stratification. A baseline MDASI-HN-NERVE score of 3.4 and a score of 3.5 at 3 to 6 months after treatment best distinguished patients with higher versus lower risk of later CN XII neuropathy. Patients above these thresholds had significantly worse CN XII neuropathy-free survival, meaning they were more likely to develop the complication over time.
A particularly important finding was that the single MDASI-HN speech/voice item also showed strong ability to discriminate latent neuropathy risk both at baseline and during early posttreatment follow-up. This suggests that even one simple symptom question may provide valuable warning information.
What the MDASI-HN-NERVE score includes
The MD Anderson Symptom Inventory-Head and Neck is a patient-reported questionnaire commonly used to assess symptom burden in head and neck cancer. In this study, the MDASI-HN-NERVE score combined six symptoms that could reflect early or evolving hypoglossal nerve dysfunction or related late effects:
Chewing/swallowing difficulty
Choking episodes
Speech/voice changes
Mucus problems
Fatigue
Dry mouth
These symptoms are not specific to CN XII neuropathy on their own. However, taken together, they may reveal a pattern that signals greater risk, especially when symptoms persist or worsen over time after treatment.
Why speech and voice changes stood out
Speech and voice changes are particularly relevant because tongue weakness can alter articulation, make speech sound imprecise, and increase the effort needed to communicate. Patients may not describe tongue weakness directly, but they often notice that speaking feels less clear or more tiring. In survivorship care, this kind of symptom can be an early clue that deserves closer examination.
The study’s finding that speech/voice scores performed well as a single-item predictor is important because it supports a streamlined screening approach. In busy oncology and head and neck clinics, a brief symptom check may be easier to implement than lengthy testing, yet still provide meaningful risk information.
Clinical implications
These results support a patient-centered surveillance strategy for survivors of oropharyngeal cancer. Rather than relying only on occasional physical examination, clinicians may be able to use routine symptom reporting to flag patients who need further assessment for cranial nerve dysfunction.
If a patient’s symptom scores are elevated, especially in the first several months after treatment, the care team might consider:
A focused cranial nerve and oral motor examination
Referral to speech-language pathology for swallowing and speech evaluation
Dietary counseling if chewing or swallowing is becoming difficult
Imaging or additional workup if the diagnosis is uncertain
Closer longitudinal monitoring for progression of neuromuscular deficits
In practice, early recognition may help reduce complications such as malnutrition, aspiration, weight loss, and social isolation from communication difficulties.
Important limitations
Although the findings are promising, several limitations should be kept in mind. First, the study was conducted at a single major cancer center, so results may not apply identically to all patient populations or treatment settings. Second, CN XII neuropathy was identified through documentation in clinical records rather than through a standardized nerve-testing protocol for every participant, which could lead to under-ascertainment. Third, symptom reporting is subjective and can be influenced by other treatment effects, such as mucositis, fibrosis, or generalized fatigue.
Also, the MDASI-HN-NERVE score is a risk stratification tool, not a diagnostic test. A high score does not prove hypoglossal neuropathy, and a low score does not fully exclude it. Instead, the score should be viewed as a practical trigger for closer evaluation.
Why this study is useful in survivorship care
Head and neck cancer survivorship increasingly focuses not only on cure, but also on preserving function and quality of life. Late neurologic toxic effects can emerge years after treatment and may be overlooked until they interfere with daily life. By linking patient-reported symptoms with later CN XII neuropathy, this study provides early evidence that routine symptom monitoring can help identify risk before severe impairment develops.
This is especially relevant for oropharyngeal cancer survivors, many of whom live for years after successful treatment and need ongoing follow-up that is both efficient and sensitive to hidden complications. A simple symptom-based tool could help bridge the gap between patient experience and clinical detection.
Take-home message
The study suggests that selected MDASI-HN symptoms, especially speech and voice changes, can help identify oropharyngeal cancer survivors at increased risk for hypoglossal neuropathy. The composite MDASI-HN-NERVE score may offer a practical way to stratify risk early after treatment and during follow-up.
While more validation is needed before broad routine use, the findings support incorporating structured symptom surveillance into head and neck cancer survivorship care. For patients and clinicians alike, paying attention to subtle changes in speech, swallowing, and tongue function may make it possible to catch CN XII neuropathy earlier and respond more effectively.
